Hopes for a quick one-two punch against melanoma have hit a snag. A Phase I trial testing Bristol-Myers Squibb's Yervoy and Roche's Zelboraf in melanoma patients was stopped after signs of liver toxicity developed in several patients.
Skin cancer drugs from Roche and Bristol-Myers Squibb, which can provide some relief to patients with deadly skin cancers and which have big futures for sales, have finally made it past the U.K. price watchdog NICE. But this only came to pass after both companies offered undisclosed discounts to the National Health Service.
Watch out, oncology drugmakers. Memorial Sloan-Kettering Cancer Center has made a move that could crimp your ambitions for premium pricing. The leading hospital says it will exclude Sanofi's ($SNY) new colorectal cancer drug Zaltrap from its treament protocols--because its price is twice as high as competing treatments, but has proven no more effective than its rivals, namely Roche's ($RHHBY) Avastin.
Will Abraxane join the new gang of melanoma fighters?
Will Abraxane join the new gang of melanoma fighters? The Celgene ($CELG) drug, a reformulated version of the chemo drug paclitaxel, kept the cancer at bay for longer than the standard chemotherapy, dacarbazine, a new study found.
A new market report says Yervoy from Bristol-Myers Squibb ($BMY) and Zelboraf from Roche ($RHHBY) have sewn up two-thirds of the market for treating advanced malignant melanoma and will underpin significant growth in sales in developed markets for a decade.
The National Institute for Health and Clinical Excellence is overhauling its appeals process. Amid criticism from the industry, including the U.K. trade group ABPI, the cost-effectiveness watchdog will add independent, non-agency members to its appeals panels.Those panels will no longer be chaired by agency types, but by outsiders.
Roche ($RHHBY) tried to sway the U.K.'s cost-effectiveness watchdogs toward its targeted melanoma drug Zelboraf. But it failed. The National Institute for Health and Clinical Excellence stuck to its rejection.
How can the industry make the process work for pharmas, payers and patients? That was the subject of a roundtable at the 2012 BIO International Convention.
The refusal by NICE on Friday to recommend that the U.K. health system buy Roche's ($RHHBY) melanoma drug Zelboraf illustrates why the debate over expensive end-of-life cancer drugs is not going to die.